Viruria in Adult Hemorrhagic Cystitis Patients Following Allogeneic Hematopoietic Stem Cell Transplantation and Implication of Antiviral Treatment

Kim, Sungyong; Lee, Jong-Wook; Lee, Kyu-Man; Cho, Byung-Sik; Eom, Ki‐Seong; Kim, Yoo-Jin; Lee, Seok; Min, Chang‐Ki; Kim, Heeje; Cho, Seok-Goo; Kim, Dong-Wook; Min, Woo-Sung; Kim, Chun-Choo

doi:10.5045/kjh.2007.42.2.114

Cited by 2 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BKV was identified in 60.0% of cases (18 of 30 patients) by a qualitative PCR-based assay. A study of 22 Allo-SCT patients who experienced HC showed that the most frequent virus detected was BKV, with an incidence of 54.5% of patients, followed by JC virus and CMV [24]. In a study of 102 children who underwent Allo-SCT for malignancies and nonmalignant diseases, HC occurred in 26 patients (25.5%), and among them, BKV was identified in 21 (80.8%) patients [25].…”

Section: Discussionmentioning

confidence: 99%

“…Hemorrhagic cystitis after SCT frequently caused prolongation of hospitalization and occasionally death [10,24,26]. Gilis et al demonstrated that the median duration of hospitalization for Allo-SCT was significantly longer for patients developing BKV-HC compared with those without BKV-HC (50 vs. 40 days, p<0.001) [26].…”

Section: Discussionmentioning

confidence: 99%

“…Gilis et al demonstrated that the median duration of hospitalization for Allo-SCT was significantly longer for patients developing BKV-HC compared with those without BKV-HC (50 vs. 40 days, p<0.001) [26]. In addition, in a series of 12 patients with BKV-HC, HC-associated renal failure was the main cause of death in two (16.7%) patients, who failed to respond to any treatment including administration of intravenous cidofovir [24]. In our study, among the seven high-grade BKV-HC patients, one died of BKV-HC-related renal failure.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

BK Virus-Hemorrhagic Cystitis Following Allogeneic Stem Cell Transplantation: Clinical Characteristics and Utility of Leflunomide Treatment

Park¹,

Lim²,

Yi³

et al. 2016

Tjh

View full text Add to dashboard Cite

Objective:BK virus-hemorrhagic cystitis (BKV-HC) is a potential cause of morbidity and mortality in patients having undergone allogeneic stem cell transplantation (Allo-SCT). We analyzed the clinical features of BKV-HC following Allo-SCT and reported the utility of leflunomide therapy for BKV-HC.Materials and Methods:From January 2005 to June 2014, among the 69 patients that underwent Allo-SCT in our institution, the patients who experienced BKV-HC were investigated retrospectively.Results:HC was observed in 30 patients (43.5%), and among them, 18 of the cases (26.1%) were identified as BKV-HC. The median age of the patients (12 males and 6 females) was 45 years (minimum-maximum: 13-63). Patients received Allo-SCT for acute myeloid leukemia (n=11), aplastic anemia (n=4), myelodysplastic syndrome (n=2), and non-Hodgkin lymphoma (n=1). The donor types were human leukocyte antigen (HLA)-matched sibling donor for six patients, HLA-matched unrelated donor for nine, and haploidentical familial donor for two. The median onset and duration of BKV-HC was on day 21 after transplantation (minimum-maximum: 7-97) and 22 days (minimum-maximum: 6-107). Eleven patients (62.1%) had grade I-II HC and seven patients (38.9%) had grade III-IV (high-grade) HC. Among the seven patients who had high-grade HC, one had complete response, one had partial response, and five had no response. Among the five nonresponders, one died of BKV-HC associated complications. The remaining four patients were treated with leflunomide, achieving complete response (n=2) and partial response (n=2). The median duration from the start of leflunomide therapy to response was 13 days (minimum-maximum: 8-17 days). All patients tolerated the leflunomide treatment well, with three patients having mild gastrointestinal symptoms, including anorexia and abdominal bloating.Conclusion:BKV-HC was commonly observed in patients with HC following Allo-SCT. In high-grade BKV-HC patients who do not respond to supportive care, leflunomide may be a feasible option without significant toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%